Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.
Download PDF

DNA methylation is associated with lung function in never smokers

Respiratory Research volume 20, Article number: 268 (2019) Cite this article

Abstract

Background

Active smoking is the main risk factor for COPD. Here, epigenetic mechanisms may play a role, since cigarette smoking is associated with differential DNA methylation in whole blood. So far, it is unclear whether epigenetics also play a role in subjects with COPD who never smoked. Therefore, we aimed to identify differential DNA methylation associated with lung function in never smokers.

Methods

We determined epigenome-wide DNA methylation levels of 396,243 CpG-sites (Illumina 450 K) in blood of never smokers in four independent cohorts, LifeLines COPD&C (N = 903), LifeLines DEEP (N = 166), Rotterdam Study (RS)-III (N = 150) and RS-BIOS (N = 206). We meta-analyzed the cohort-specific methylation results to identify differentially methylated CpG-sites with FEV1/FVC. Expression Quantitative Trait Methylation (eQTM) analysis was performed in the Biobank-based Integrative Omics Studies (BIOS).

Results

A total of 36 CpG-sites were associated with FEV1/FVC in never smokers at p-value< 0.0001, but the meta-analysis did not reveal any epigenome-wide significant CpG-sites. Of interest, 35 of these 36 CpG-sites have not been associated with lung function before in studies including subjects irrespective of smoking history. Among the top hits were cg10012512, cg02885771, annotated to the gene LTV1 Ribosome Biogenesis factor (LTV1), and cg25105536, annotated to Kelch Like Family Member 32 (KLHL32). Moreover, a total of 11 eQTMS were identified.

Conclusions

With the identification of 35 CpG-sites that are unique for never smokers, our study shows that DNA methylation is also associated with FEV1/FVC in subjects that never smoked and therefore not merely related to smoking.

Background

Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory lung disease characterized by persistent airway obstruction that causes severe respiratory symptoms and poor quality of life [1]. Although smoking is generally considered the main environmental risk factor, estimations are that 25–45% of patients with COPD have never smoked [2]. Despite extensive research, the etiology of COPD remains incompletely understood. It is known that the development of this complex heterogeneous disease is influenced by both genetic and environmental factors, as well as their interactions [3,4,5,6]. As interface between the inherited genome and environmental exposures, an important role has been postulated for the epigenome [7]. The epigenome includes multiple epigenetic mechanisms that affect gene expression without modifying the DNA sequence. These epigenetic mechanisms are highly dynamic and respond to environmental exposures, ageing and diseases [8]. One such epigenetic mechanism is DNA methylation, which involves the binding of a methyl group to a cytosine base located adjacent to a guanine base. Methylation of these so called CpG-sites in regulatory regions of the DNA generally result in decreased expression of a particular gene [9].

So far, only a few studies have investigated the association between DNA methylation in peripheral blood and COPD or lung function using an epigenome-wide hypothesis free approach [10,11,12,13,14,15,16,17]. Although findings across the studies are not consistent, there is suggestive evidence that alterations in DNA methylation might play a role in the etiology of COPD. However, in previous studies, subjects were mainly included irrespective of smoking status, thus including current smokers, ex-smokers and never smokers. As a consequence, it is currently not known if there are differences in DNA methylation between healthy individuals and patients with COPD who have never smoked. Recently, we studied the association between epigenome-wide DNA methylation and COPD in both current smokers and never smokers [16]. Although we did not find any epigenome-wide significant association in current smokers nor in never smokers, the associations between DNA methylation and COPD were different between both groups. Hence, by further exploring the role of DNA methylation in a much larger set of never smokers together with a continuous measurement of lung function, we might be able to reveal important novel insights in the etiology of COPD. In this study, we aim to assess the association between DNA methylation and lung function in never smokers, meta-analyzing four independent population-based cohorts.

Methods

Study population

To study the association between epigenome-wide DNA methylation and lung function, defined as the ratio between the Forced Expiratory Volume in 1 s (FEV1) and Forced Vital Capacity (FVC), in never smokers, we performed a meta-analysis in four different cohorts. Two cohorts originated from the LifeLines population-based cohort study [18]: the LifeLines COPD & Controls DNA methylation study [16, 19] (LL COPD&C, n = 903) and the LifeLines DEEP study [20] (LLDEEP, n = 166). The two other cohorts originated from the population-based Rotterdam study (RS) [21]: The first visit of the third RS cohort (RS-III-1, n = 150) and a cohort selected for the Biobank-based Integrative Omics Studies (BIOS) project (RS-BIOS, n = 206). Both population-based cohort studies were approved by the local university medical hospital ethical committees and all participants signed written informed consent. In all cohorts, never smoking was defined based on self-reported never smoking history and 0 pack years included in the standardized questionnaires.

Measurements

Lung function

Within the LifeLines population-based cohort study, pre-bronchodilator spirometry was performed with a Welch Allyn Version 1.6.0.489, PC-based Spiroperfect with CA Workstation software according to ATS/ERS guidelines. Technical quality and results were evaluated by well-trained assistants and difficult to interpret results were re-evaluated by a lung physician. Within the population-based Rotterdam study, pre-bronchodilator spirometry was performed during the research center visit using a SpiroPro portable spirometer (RS-III-1) or a Master Screen® PFT Pro (RS-BIOS) by trained paramedical staff according to the ERS/ATS Guidelines. Spirometry results were analyzed by two researchers and verified by a specialist in pulmonary medicine.

DNA methylation

In all four cohorts, DNA methylation levels in whole blood were determined with the Illumina Infinium Methylation 450 K array. Data was presented as beta values (ratio of methylated probe intensity and the overall intensity) ranging from 0 to 1. Quality control has been performed for all datasets separately as described before [19, 22]. After quality control, data was available on 396,243 CpG-sites in all four datasets.

Statistical analysis

Epigenome-wide association study and meta-analysis

We performed an epigenome-wide association study (EWAS) on lung function defined as FEV1/FVC in all four cohorts separately using robust linear regression analysis in R. The analysis was adjusted for the potential confounders age and sex. To adjust for the cellular heterogeneity of the whole blood samples, we included proportional white blood cell counts of mononuclear cells, lymphocytes, neutrophils and eosinophils, obtained by standard laboratory techniques. For LL COPD&C, we adjusted for technical variation by performing a principal components analysis using the 220 control probes incorporated in the Illumina 450 k Chip. The 7 principal components that explained > 1% of the technical variation were included in the analysis. For LLDEEP, data on technical variance was not accessible. For the two RS cohorts, we included the position on the array and array number to adjust for technical variation. Regression estimates from all four individual EWA studies were combined by a weighted by the inverse of the variance random-effect meta-analysis using the effect estimates and standard errors in “rmeta” package in R. CpG-sites with a p-value below 1.26 × 10^− 7 (Bonferroni corrected p-value by number of CpG-sites 0.05/396243) were considered epigenome-wide significant. CpG-sites with a p-value below 0.0001 in the meta-analysis were defined as top associations in our study.

Expression quantitative trait methylation (eQTM) analysis

To assess whether top associations were also associated with gene expression levels, we used the never smokers included in the Biobank-based Integrative Omics Studies (BIOS). For all cohorts separately, reads were normalized to counts per million. To adjust for technical variation for gene expression and DNA methylation, principal component analysis was conducted on the residual normalized counts and beta-values excluding the potential confounders age and gender. Principal components that explained more than 5% of the technical variation in gene expression or DNA methylation were included in the analysis. Subsequently, robust linear regression analysis was performed on the CpG-sites and the genes within 1 MB around the CpG-sites. The analyses were adjusted for the potential confounders age, sex and technical variation by principal components as stated before. The individuals eQTM analysis were combined by a random-effect meta-analysis using the effect estimates and standard errors in RMeta. An eQTM was considered significant when the Bonferroni-adjusted p-value for the number of genes within 1 MB around the CpG-sites was below 0.05.

Results

Subject characteristics

An overview of the characteristics of the subjects included in the study is shown in Table 1. LL COPD&C was the largest cohort included in this meta-analysis. Notably, since this cohort is a non-random selection from the LifeLines cohort study with COPD (defined as FEV1/FVC < 0.70) as one of the selection criteria, the percentages of COPD cases should not be interpreted as prevalence.

Table 1 Subject characteristics of the subjects from the four different DNA methylation datasets
Full size table

Meta-analysis of the four epigenome-wide association studies

The meta-analysis of the four different cohorts did not reveal CpG-sites that were epigenome wide significantly associated with FEV1/FVC. We identified 36 CpG-sites as our top associations (Table 2). The Manhattan plot of the meta-analysis is shown in Fig. 1a. Forest plots of the three most significant CpG-sites cg10012512, located in the intergenic region of chromosome 7q36.3 (p=5.94 × 10^− 7), cg02285771, annotated to LTV1 Ribosome Biogenesis Factor (LTV1) (p=4.10 × 10^− 6) and cg25105536, annotated to Kelch Like Family Member 32 (KLHL32) (p=9.09 × 10^− 6) are shown in Fig. 1b-d. An overview of all CpG-sites associated with FEV1/FVC at nominal p-value of 0.05 can be found in Additional file 1: Table S1.

Table 2 Results of the meta-analysis and individual EWA studies on FEV1/FCV in never smokers
Full size table
Fig. 1
figure1

Manhattan and forest plots of the meta-analysis on four independent epigenome-wide association studies on FEV1/FVC in never smokers. a Manhattan plot in which every dot represents an individual CpG-site. Location on the X-axis indicated the chromosomal position and location on the Y-axis indicates the inversed log [10] p-value of the meta-analysis. Dotted horizontal line indicates p-value of 0.0001, horizontal fixed line indicates epigenome-wide significance (p-value < 0.05/396,243 = 1.26 × 10^− 7). b-d Forest plots showing the effect estimates and standard errors of the 4 independent EWA studies and meta-analysis for the top hits cg10012512 (b), cg028885771 (c) and cg25105536 (d)

Full size image

The direction of the effect of the 36 top CpG-sites did not change in a sensitivity analysis in the LL COPD&C cohort excluding the subjects that were exposed to environmental tobacco smoke (ETS)(N=659 subjects) (Additional file 2: Table S2).

Expression quantitative trait methylation (eQTM) analysis

In total, 803 genes were located within 2 MB of the 36 CpG-sites. The expression of 11 genes was significantly associated with DNA methylation levels at the 9 different CpG-sites (Table 3). DNA methylation at cg25105536, annotated to KLHL32, was significantly associated with gene expression levels of KLHL32. DNA methylation levels at cg08065963, located in the intergenic region on chromosome 16 and not yet annotated to a gene, showed a significant association with gene expression levels of 4-Aminobutyrate Aminotransferase (ABAT). For the other 7 CpG-sites, DNA methylation levels were associated with gene expression levels of one or two genes other than the previously annotated genes. An overview of the association between DNA methylation and gene expression levels of all genes can be found in Additional file 3: Table S3.

Table 3 Overview of the results of the meta-analysis of the eQTM analysis
Full size table

Discussion

This study is the first large general population-based EWA study on lung function in never smokers. So far, virtually all EWA studies on the origin of COPD included subjects with a history of cigarette smoking. As a consequence, these studies mainly addressed the origins of COPD in response to smoking. It is unclear if the results of these studies help to explain the etiology of COPD or rather explain the contribution of cigarette smoke towards the disease. Therefore, our study importantly contributes to the current understanding of COPD in never smokers.

We identified 36 CpG-sites that were significantly associated with FEV1/FVC at p-value below 0.0001. The top hit of our meta-analysis, cg10012512, is located in the intergenic region of chromosome 7q36.3. It is therefore not possible to speculate on the functional effect of differences in DNA methylation at this specific CpG-site and how these differences may affect FEV1/FVC. While associations found with an eQTM analysis may help to get more insight in the function of a CpG-site, our eQTM analysis did not reveal any nominal significant associations for cg10012512. However, this CpG-site was differentially methylated between never smokers and current smokers [23]. Presumably, this CpG-site does also respond to other inhaled deleterious substances, which in turn affects lung function. The second top hit, cg02885771 located on chromosome 6q24.2 is annotated LTV1. Previously, this CpG-site has been associated with asthma in airway epithelial cells [24] and LTV1 was shown to be expressed in lung tissue in the Genotype Tissue Expression (GTEx) project. Although studies in yeast describe LTV1 as a conserved 40S-associated biogenesis factor that functions in small subunit nuclear export, a specific role for LTV1 in respiratory diseases is not known [25]. The third top hit, cg25105536, is annotated to KLHL32 on chromosome 6q16.1 and we found a significant association between DNA methylation levels of cg25105536 and gene expression levels of KLHL32. The function of KLHL32 is poorly understood, however, four genetic variants in the KLHL32 gene have been associated with FEV1 and FEV1/FVC in African American subjects with COPD and a history of smoking [26]. Notwithstanding the fact that these associations were only identified in a specific group, it might suggest a role for KLHL32 in the respiratory system. Next to KLHL32, we found that gene expression levels of 10 additional genes were significantly associated with DNA methylation levels at one of the 36 CpG-sites. cg08065963, which was not yet annotated to a gene, was significantly associated with 4-Aminobutyrate Aminotransferase (ABAT). Interestingly, a role for ABAT in COPD has not been described before. The remaining nine genes were other genes than the annotated genes of the particular CpG-sites. This suggest that the CpG-sites may also regulate distant genes within a region of 2 MB, which complicates the functional assessment of differences in DNA methylation even further.

To the best of our knowledge, there are eight studies in literature describing the association between DNA methylation and lung function (Table 4). Six of these studies included both subjects with and without a history of cigarette smoking and, except for the study by Qui et al., adjusted for smoking status in the statistical analysis. In addition, the recent study by Imboden et al. performed analyses with and without adjustment for smoking status and pack years. Altogether, these seven studies identified 462 unique CpG-sites. Interestingly, none of the 36 CpG-sites from our meta-analysis in never smokers were among these 462 previously identified CpG-sites (Table 5). Apparently these 36 CpG-sites are only associated with lung function level in never smokers. The fact that 17 CpG-sites (47%) were associated at nominal p-value < 0.05 with COPD (dichotomously defined as the ratio of FEV1/FVC below 70%) in our previously EWAS stratified for never smoking, further underscores this assumption [16]. There is, however, one exception, since cg22742965, annotated to Transmembrane Protein With EGF Like And Two Follistatin Like Domains 2 (TMEFF2), was also significantly associated with COPD in smokers. Most likely, this CpG-site shows a general response to inhaled deleterious substances such as cigarette smoke and other yet unknown substances.

Table 4 Overview of studies reporting results of differential DNA methylation with lung function or COPD in whole blood
Full size table
Table 5 Overview of CpG location, gene annotation, gene function and literature comparison of the top 36 CpG-sites of the meta analysis
Full size table

Assuming that the observed differential DNA methylation at the majority of the CpG-sites in our study occurs without exposure to smoking, the question arises why this differential DNA methylation is observed. One possible explanation may be that other factors within the environment such as air pollution and job-related exposures are responsible for the observed differences in DNA methylation. Recently, we studied the epigenome-wide association between DNA methylation and exposure to air pollution and job-related exposures in a selection of the LifeLines population cohort including both never and current smokers [19, 27]. While we did find significant associations, none of them were replicated in independent cohorts. Additional analyses in never smokers for this paper did not reveal novel associations between DNA methylation and environmental exposures (Additional file 4: Table S4 and Additional file 5: Figure S1). This might potentially be due to lack of power, since only a small percentage of the subjects that have never smoked in the LL COPD&C cohort have been exposed to environmental exposures. Moreover, exposure levels to air pollution in the LL COPD&C are relatively low compared to the average Dutch levels determined within the 2012 Dutch national health survey as described by Strak et al [28]. Next to environmental exposures, another explanation may be that a reduced lung function level precedes the differences in DNA methylation. However, with the cross-sectional design of this study, we cannot derive conclusions on the direction of the association and causality. Large longitudinal studies are required to investigate causality between DNA methylation and FEV1/FVC. Moreover, this will give the opportunity to investigate if low levels of FEV1 and decline in FEV1 over the years is associated with DNA methylation in never smokers.

Conclusions

With this study we show that epigenetics indeed may be associated with FEV1/FVC in subjects who never smoked. Moreover, since 35 out of the 36 identified CpG-sites are unique for never smokers, our data suggest that factors other than smoking affect FEV1/FVC via DNA methylation.

Availability of data and materials

The datasets and/or analyzed during the current study are available from the corresponding authors on reasonable request. Summary statistics of the meta-analysis and the four individual EWAS studies with nominal p-value of 0.05 have been made freely available as Additional file.

Abbreviations

ATS:

American Thoracic Society

BIOS:

Biobank-based Integrative Omics Studies

COPD:

Chronic Obstructive Pulmonary Disease

CpG:

Cytosine-phosphate-Guanine

DNA:

Deoxyribonucleic acid

eQTM:

Expression Quantitative Trait Methylation

ERS:

European Respiratory Society

ETS:

Environmental tobacco smoke

EWAS:

Epigenome-wide association study

FEV1 :

Forced expiratory volume in 1 s

FVC:

Forced vital capacity

GTEx:

Genotype tissue expression

References

  1. 1.

    From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: http://www.goldcopd.org/.

  2. 2.

    Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–43.

  3. 3.

    van der Plaat DA, de Jong K, Lahousse L, Faiz A, Vonk JM, van Diemen CC, et al. Genome-wide association study on the FEV1/FVC ratio in never-smokers identifies HHIP and FAM13A. J Allergy Clin Immunol. 2017;139(2):533-40.

  4. 4.

    de Jong K, Boezen HM, Kromhout H, Vermeulen R, Postma DS, Vonk JM. Association of occupational pesticide exposure with accelerated longitudinal decline in lung function. Am J Epidemiol. 2014;179(11):1323–30.

  5. 5.

    de Jong K, Vonk JM, Timens W, Bosse Y, Sin DD, Hao K, et al. Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels. J Allergy Clin Immunol. 2015;136(6):1664–72.e1–14.

  6. 6.

    Hobbs BD, de Jong K, Lamontagne M, Bosse Y, Shrine N, Artigas MS, et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017;49(3):426–32.

  7. 7.

    Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8(4):253–62.

  8. 8.

    Yang IV, Lozupone CA, Schwartz DA. The environment, epigenome, and asthma. J Allergy Clin Immunol. 2017;140(1):14–23.

  9. 9.

    Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92.

  10. 10.

    Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med. 2012;185(4):373–81.

  11. 11.

    Bolund ACS, Starnawska A, Miller MR, Schlunssen V, Backer V, Borglum AD, et al. Lung function discordance in monozygotic twins and associated differences in blood DNA methylation. Clin Epigenetics. 2017;9:132-017-0427-2 eCollection 2017.

  12. 12.

    Lee MK, Hong Y, Kim SY, Kim WJ, London SJ. Epigenome-wide association study of chronic obstructive pulmonary disease and lung function in Koreans. Epigenomics. 2017;9(7):971–84.

  13. 13.

    Busch R, Qiu W, Lasky-Su J, Morrow J, Criner G, DeMeo D. Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations. Respir Res. 2016;17(1):143-016-0459-8.

  14. 14.

    Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, et al. Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet. 2012;8(4):e1002629.

  15. 15.

    Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, et al. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian birth cohort 1936. Int J Epidemiol. 2015;44(4):1388–96.

  16. 16.

    de Vries M, van der Plaat DA, Vonk JM, Boezen HM. No association between DNA methylation and COPD in never and current smokers. BMJ Open Respir Res. 2018;5(1):e000282-2018-000282 eCollection 2018.

  17. 17.

    Imboden M, Wielscher M, Rezwan FI, Amaral AFS, Schaffner E, Jeong A, et al. Epigenome-wide association study of lung function level and its change. Eur Respir J. 2019;54(1).

  18. 18.

    Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort profile: lifeLines, a three-generation cohort study and biobank. Int J Epidemiol. 2015;44(4):1172–80.

  19. 19.

    van der Plaat DA, de Jong K, de Vries M, van Diemen CC, Nedeljkovic I, Amin N, et al. Occupational exposure to pesticides is associated with differential DNA methylation. Occup Environ Med. 2018;75(6):427–35.

  20. 20.

    Tigchelaar EF, Zhernakova A, Dekens JA, Hermes G, Baranska A, Mujagic Z, et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open. 2015;5(8):e006772-2014-006772.

  21. 21.

    Ikram MA, Brusselle GGO, Murad SD, van Duijn CM, Franco OH, Goedegebure A, et al. The Rotterdam study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017;32(9):807–50.

  22. 22.

    Ligthart S, Steenaard RV, Peters MJ, van Meurs JB, Sijbrands EJ, Uitterlinden AG, et al. Tobacco smoking is associated with DNA methylation of diabetes susceptibility genes. Diabetologia. 2016;59(5):998–1006.

  23. 23.

    Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet. 2016;9(5):436–47.

  24. 24.

    Nicodemus-Johnson J, Myers RA, Sakabe NJ, Sobreira DR, Hogarth DK, Naureckas ET, et al. DNA methylation in lung cells is associated with asthma endotypes and genetic risk. JCI Insight. 2016;1(20):e90151.

  25. 25.

    Merwin JR, Bogar LB, Poggi SB, Fitch RM, Johnson AW, Lycan DE. Genetic analysis of the ribosome biogenesis factor Ltv1 of Saccharomyces cerevisiae. Genetics. 2014;198(3):1071–85.

  26. 26.

    Lutz SM, Cho MH, Young K, Hersh CP, Castaldi PJ, McDonald ML, et al. A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. BMC Genet. 2015;16:138-015-0299-4.

  27. 27.

    de Lichtenfels AJFC, van der Plaat DA, de Jong K, van Diemen CC, Postma DS, Nedeljkovic I, et al. Long-term air pollution exposure, genome-wide DNA methylation and lung function in the lifelines cohort study. Environ Health Perspect. 2018;126(2):027004.

  28. 28.

    Strak M, Janssen N, Beelen R, Schmitz O, Vaartjes I, Karssenberg D, et al. Long-term exposure to particulate matter, NO2 and the oxidative potential of particulates and diabetes prevalence in a large national health survey. Environ Int. 2017;108:228–36.

Download references

Acknowledgements

The Biobank-Based Integrative Omics Studies (BIOS) Consortium is funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO 184.021.007).

Funding

This work was supported by consortium grant number 4.1.13.007 of the Lung foundation Netherlands. The LifeLines initiative has been made possible by funds from FES (Fonds Economische Structuurversterking), SNN (Samenwerkingsverband Noord Nederland) and REP (Ruimtelijk Economisch Programma).

Author information

Affiliations

  1. University of Groningen, University Medical Center Groningen, Department of Epidemiology, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
    • Maaike de Vries
    • , Diana A. van der Plaat
    • , Judith M. Vonk
    •  & H. Marike Boezen
  2. University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, The Netherlands
    • Maaike de Vries
    • , Diana A. van der Plaat
    • , Judith M. Vonk
    •  & H. Marike Boezen
  3. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
    • Ivana Nedeljkovic
    • , Lies Lahousse
    • , Guy G. Brusselle
    • , Najaf Amin
    •  & Cornelia M. van Duijn
  4. University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
    • Alexandra Zhernakova
  5. Department of Bioanalysis, FFW, Ghent University, Ghent, Belgium
    • Lies Lahousse
  6. Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
    • Guy G. Brusselle
  7. Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • Guy G. Brusselle
Authors
  1. Maaike de Vries
    View author publications
    You can also search for this author in
  2. Ivana Nedeljkovic
    View author publications
    You can also search for this author in
  3. Diana A. van der Plaat
    View author publications
    You can also search for this author in
  4. Alexandra Zhernakova
    View author publications
    You can also search for this author in
  5. Lies Lahousse
    View author publications
    You can also search for this author in
  6. Guy G. Brusselle
    View author publications
    You can also search for this author in
  7. Najaf Amin
    View author publications
    You can also search for this author in
  8. Cornelia M. van Duijn
    View author publications
    You can also search for this author in
  9. Judith M. Vonk
    View author publications
    You can also search for this author in
  10. H. Marike Boezen
    View author publications
    You can also search for this author in

Consortia

BIOS Consortium

Contributions

MdV, AZ, LL, GGB, NA, CMvD, JMV, and HMB were involved in conception and design of the research. MdV, IN, and DAvdP performed the analyses. MdV and HMB interpreted the results. MdV prepared figures and drafted the manuscript. HMB, IN, and JMV critically reviewed and revised the manuscript. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Maaike de Vries.

Ethics declarations

Ethics approval and consent to participate

LifeLines population-based cohort study

Written informed consents was provided by all included subjects and the study was approved by the Medical Ethics Committee of the University Medical Center Groningen (2007/152).

The Rotterdam Study

Written informed consents to participate in the study and to obtain information from their treating physicians was provided by all participants. The study has been approved by the Medial Ethics Committee of the Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Population Studies Act: Rotterdam Study.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

de Vries, M., Nedeljkovic, I., van der Plaat, D.A. et al. DNA methylation is associated with lung function in never smokers. Respir Res 20, 268 (2019). https://doi.org/10.1186/s12931-019-1222-8

Download citation

Keywords

  • DNA methylation
  • Never smokers
  • FEV1/FVC
  • EWAS
  • COPD

Respiratory Research

ISSN: 1465-993X

Contact us